

DIAGNÓSTICOS DA AMÉRICA S.A.
Publicly Held Company
Corporate Taxpayer ID (CNPJ/MF): 61.486.650/0001-83
Company Registry (NIRE): 35.300.172.507

MATERIAL FACT

DIAGNÓSTICOS DA AMÉRICA S.A. (B3: DASA3) ("**Company**" or "**Dasa**"), in compliance with article 157, paragraph 4, of Federal Law 6,404/1976, as amended, and in accordance with CVM Resolution 44/2021, as amended, hereby informs its shareholders and the market that on this date, the Board of Directors of the Company approved the succession plan for the current Chief Executive Officer ("CEO"), Pedro de Godoy Bueno, which includes the nomination of Lício Tavares Ângelo Cintra to the position of CEO of Dasa with effect from February 1, 2024.

- The transition is planned to occur in three phases, with clear definition of roles to ensure disciplined rollout of the strategy and the maturity of its governance model.
 - **Phase 1 (August 2023 to February 2024):** Still as the CEO, Pedro will set the pace of leadership transition on the management front, and will assist Lício in getting to know the Company and the team. As Chief Operating Officer ("COO"), Lício will lead the execution and operations of the core business: hospitals, diagnostics and commercial;
 - **Phase 2 (February 2024 to February 2025):** As Executive Vice Chairman of the Board of Directors and a member of the People Committee, Pedro will ensure the disciplined direction and rollout of the strategy, and will support Lício in his role as CEO; and
 - **Phase 3 (starting February 2025):** Pedro will become Vice Chairman of the Board of Directors of Dasa, ceasing to hold an executive position.
- During his trajectory of over eight years at Dasa, Pedro led the Company's accelerated growth cycle, creating a new operational model for the healthcare sector that began with the turnaround of a diagnostics company into Brazil's largest integrated health network, to create an end-to-end, innovative, sustainable and smart ecosystem that currently serves over 23 million Brazilians annually and operates with over 50,000 employees and 250,000 partner physicians. In this period, the Company's revenues leaped from R\$3 billion (2015) to R\$14 billion (2022).

Under his leadership, the Company's operations expanded to the hospital sector, making Dasa one of Brazil's largest private hospital networks, and to the oncology sector, becoming one of the leading players in the segment. Pedro has also overseen more than 20 mergers and acquisitions in the last three years and a busy agenda of asset integrations. Another remarkable achievement was the creation of Nav, Brazil's largest health platform with over 7 million users.

As for capital markets, Pedro played a pivotal role in the Company's successful re-IPO in 2021, which raised R\$3.3 billion and repositioned Dasa in the B3's Novo Mercado segment, the highest level of corporate governance. Moreover, in 2022, Pedro led the follow-on offering, which raised fresh capital of R\$1.7 billion for the Company, an important step in optimizing Dasa's capital structure after two years focused on asset integration.

Pedro holds a degree in Economics from the Pontifícia Universidade Católica in Rio de Janeiro, has 17 years of experience in the healthcare sector and participated in the merger Amil-UHG (one of the largest U.S. transactions in the country so far). He is the cofounder of DNA Capital, an investment manager specializing in health, and has worked in leading financial companies.

The Company and the Board of Directors thank him for all his contributions as the CEO of Dasa in recent years and reiterate their enthusiasm about the strategic contributions he will make in his new position as Executive Vice Chairman of the Board of Directors.

- The nomination of Lício Tavares Ângelo Cintra, an executive with vast experience in the healthcare sector strengthen the Company's commitment to deliver the strategy and results, with the focus on operations, efficiency gains, operational performance, strong growth and expansion of market share of Dasa's business units and on creating value for the entire health chain in Brazil.

Lício has used his 18 years of experience in the healthcare sector to bring his expertise in profound transformations and growth in all his roles. His excellent networking within the sector will help expand innovative partnerships with clients. He joins the Company after almost three years at Hapvida, where he served on the Board of Directors and was Vice President - Commercial and M&A. In these positions, he brought strategic inputs to the business at a time when the company made diverse acquisitions, including the merger with Grupo NotreDame Intermédica. Prior to that, Lício worked for 14 years in the São Francisco Group, 10 of them at the helm, when he consolidated a business model composed of a unique proposition for access to Brazil's Midwest and South regions, as well as the interior region of São Paulo. Under his management, the company was recognized as client-centric, people-focused and leveraging a policy of meritocracy and talent development.

Lício holds a degree in Electrical Engineering from Universidade Presbiteriana Mackenzie, has completed a specialization program in Business Administration from FGV and holds an MBA in Controllershship and Finance from USP (FUNDACE) and an International Executive MBA from FIA.

The Company and the Board of Directors firmly believe Lício will contribute significantly to further expanding Dasa's capacity to deliver value by consolidating a new model of strategic and operational leadership. Pedro's transformational vision combined with his vast experience should accelerate Dasa's ambitions of expanding access to and sustainability in Brazil's healthcare sector and will be one more step towards enhancing the level of corporate governance at the Company.

The Company will keep the market informed of further significant developments in this regard.

Barueri, June 27, 2023.

Glauco Desiderio
Investor Relations Officer